Segment and Geographic Information (Tables)

3 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of financial information for reportable segments

	Three Months Ended December 31,
	2023		2022
Revenue:
Sample Management Solutions	$	79,005	$	75,455
Multiomics		62,720		61,089
B Medical Systems		12,592		41,822
Total revenue	$	154,317	$	178,366
Adjusted operating (loss) income:
Sample Management Solutions	$	(856)	$	(2,998)
Multiomics		(3,451)		(3,265)
B Medical Systems		(4,409)		6,303
Segment adjusted operating (loss) income		(8,716)		40
Amortization of completed technology		5,627		4,168
Purchase accounting impact on inventory		—		2,869
Amortization of intangible assets other than completed technology		6,862		7,372
Restructuring charges		1,120		1,461
Merger and acquisition costs and costs related to share repurchase(1)		4,321		11,838
Other unallocated corporate expenses		31		17
Total operating loss		(26,677)		(27,685)
Interest income, net		10,081		10,665
Other, net		682		1,145
Loss before income taxes	$	(15,914)	$	(15,875)
(1) Includes expenses related to governance-related matters.

Schedule of reconciliation of reportable segment assets to corresponding consolidated amounts

Assets:	December 31, 2023		September 30, 2023
Sample Management Solutions	$	874,037	$	675,708
Multiomics		490,898		534,437
B Medical Systems		376,613		511,640
Total assets	$	1,741,548	$	1,721,785

	December 31,		September 30,
	2023		2023
Segment assets	$	1,741,548	$	1,721,785
Cash and cash equivalents, restricted cash, and marketable securities		1,051,395		1,134,256
Deferred tax assets		1,341		571
Other assets		30,030		29,108
Total assets	$	2,824,314	$	2,885,720

Schedule of revenue from external customers attributed to geographic areas

	Three Months Ended December 31,
	2023		2022
Geographic Location:
United States	$	90,592	$	87,717
Africa		7,511		17,210
China		14,898		13,408
United Kingdom		5,699		5,413
Rest of Europe		24,832		39,422
Asia Pacific/Other		10,785		15,196
Total revenue	$	154,317	$	178,366